{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:56:53Z","timestamp":1790143013555,"version":"4.0.1"},"reference-count":110,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T00:00:00Z","timestamp":1366243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:sec><jats:title>Disease Overview<\/jats:title><jats:p>Immunoglobulin (Ig) light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of Ig light chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral\/autonomic neuropathy, and atypical multiple myeloma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis<\/jats:title><jats:p>Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple\u2010green birefringence is required for diagnosis. Invasive organ biopsy is not required because amyloid deposits can be found in bone marrow biopsy or subcutaneous fat aspirate in 85% of patients. Verification that amyloid is of immunoglobulin origin is mandatory.<\/jats:p><\/jats:sec><jats:sec><jats:title>Prognosis<\/jats:title><jats:p>N\u2010terminal pro\u2013brain natriuretic peptide (NT\u2010proBNP), serum troponin T, and immunoglobulin free light chain values are used to classify patients into four groups of similar size; median survivals are 94.1, 40.3, 14.0, and 5.8 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Therapy<\/jats:title><jats:p>All patients with a visceral amyloid syndrome require therapy to prevent deposition of amyloid in other viscera and prevent progressive organ failure of involved sites. Stem cell transplant (SCT) is preferred, but only 20% of patients are eligible. Requirements for safe SCT include NT\u2010proBNP &lt;5,000 ng\/mL, troponin T\u2009&lt;\u20090.06 ng\/mL, age &lt;70 years, &lt;3 organs involved, and serum creatinine \u22641.7 mg\/dL. Nontransplant candidates can be offered melphalan\u2010dexamethasone. Pomalidomide appears to have activity, as do other combinations of chemotherapy with agents such as cyclophosphamide\u2010thalidomide (or lenalidomide or bortezomib)\u2010dexamethasone, bortezomib\u2010dexamethasone, and melphalan\u2010prednisone\u2010lenalidomide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Future Challenges<\/jats:title><jats:p>Late diagnosis remains a major obstacle to initiating effective therapy when organ dysfunction is still recoverable. Recognizing the presenting syndromes is necessary for improving survival. Am. J. Hematol. 88:417\u2013425, 2013. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajh.23400","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T15:03:01Z","timestamp":1366297381000},"page":"416-425","source":"Crossref","is-referenced-by-count":68,"title":["Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment"],"prefix":"10.1002","volume":"88","author":[{"given":"Morie A.","family":"Gertz","sequence":"first","affiliation":[{"name":"Division of Hematology Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-125526"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-009-8163-9"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.5858\/134.4.545"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-974"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2010.n.027"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-011-0239-5"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2008.11.006"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.84"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2010.05.001"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmrj.2008.11.011"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcu.20552"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-010-0108-7"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2006.07.107"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1028-8"},{"key":"e_1_2_11_16_1","first-page":"105","article-title":"Screening panels for monoclonal gammopathies: Time to change","volume":"30","author":"Katzmann JA","year":"2009","journal-title":"Clin Biochem Rev"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.04.024"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.307"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054494"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.524329"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.117143"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181abdfa7"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-010-0909-5"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-009-0857-9"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20101"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2009.03799.x"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvoice.2008.07.006"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.03.069"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.11.019"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506120600876773"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4148"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acthis.2006.03.010"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/13506120500535768"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-230722"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.261"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-365510"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02890310"},{"key":"e_1_2_11_39_1","article-title":"Relationship between monoclonal gammopathy and cardiac amyloid type","author":"Maleszewski JJ","journal-title":"Cardiovasc Pathol"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0b013e3181bdba8f"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2009.11.013"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0390"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc072918"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701684518"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-032987"},{"key":"e_1_2_11_47_1","first-page":"633","article-title":"Uniform risk\u2010stratification and response criteria are paving the way to evidence\u2010based treatment of AL amyloidosis","volume":"25","author":"Palladini G","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_11_48_1","article-title":"Higher plasma cell burden predicts for early death in patients with AL amyloidosis [abstract 1893]","volume":"116","author":"Chee CE","year":"2010","journal-title":"Blood"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-290668"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-009-0013-6"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.3.297"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(72)93014-0"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197507000-00001"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.10.026"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070484"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.01.022"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.09.005"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.234"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0480"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-370031"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099481"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27660"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.234"},{"key":"e_1_2_11_66_1","article-title":"Refinement in patient selection to reduce treatment\u2010related mortality from SCT in amyloidosis","author":"Gertz MA","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11413"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32801494c6"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.239"},{"key":"e_1_2_11_70_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.370.370","article-title":"Pre\u2010stem cell transplant induction therapy does not affect post\u2010transplant survival in light chain (AL) amyloidosis [abstract 370]","volume":"116","author":"Madan S","year":"2010","journal-title":"Blood"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21948"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)89487-9"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361702"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03541.x"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2788"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-076034"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2271"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07327.x"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253237"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279901"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390930"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388462"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1526-9655(11)70186-5"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.3109\/13506120309041743"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0600-y"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035352"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.10.1298"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-030544"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294405"},{"key":"e_1_2_11_90_1","article-title":"Melphalan, lenalidomide and dexamethasone for the treatment of AL amyloidosis: Results of a phase II trial","author":"Sanchorawala V","journal-title":"Haematologica"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-407791"},{"key":"e_1_2_11_92_1","article-title":"A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis","author":"Palladini G","journal-title":"Haematologica"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-396903"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq482"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21822"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1244-x"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-413161"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11627"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12136"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-203398"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0710-x"},{"key":"e_1_2_11_102_1","article-title":"Bortezomib and dexamethasone consolidation following risk\u2010adapted melphalan and stem cell transplantation for patients with newly diagnosed light\u2010chain amyloidosis","author":"Landau H","year":"2012","journal-title":"Leukemia"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8220"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1062-6"},{"key":"e_1_2_11_105_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.988.988","article-title":"A European collaborative study of treatment outcomes in 428 patients with systemic AL amyloidosis [abstract 988]","volume":"116","author":"Wechalekar AD","year":"2010","journal-title":"Blood"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.09.011"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr067"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00920.x"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04326.x"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs492"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5235"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23400","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23400","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T01:26:51Z","timestamp":1700616411000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,18]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1002\/ajh.23400"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23400","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,18]]}}}